DALLAS, May 20 (UPI) -- Getting treatment quickly can make all the difference after a stroke, so it is important to be able to recognize the signs of stroke, a U.S. physician says. Dr. Mark Goldberg of The University of Texas Southwestern Medical Center in Dallas said not enough people recognize the symptoms of a stroke, and as a consequence only 5 percent of stroke victims receive an effective clot-busting drug called tPA, which should be administered within 3 hours of a stroke. Sudden problems with vision, walking and speaking are stroke indicators, as well as sudden paralysis, droopiness, or numbness on one side of the face or body, Goldberg said. Another potential symptom of stroke is a sudden, severe headache that can be accompanied by vomiting or dizziness. The neurologist said most strokes don't immediately render people unconscious, so many victims simply think they are tired and in need of a nap. Stroke-victim advocates have developed the acronym FAST to describe both what should be done and when it should done. FAST stands for: -- Face: Ask the person to smile. Does one side of the face droop? -- Arms: Ask the person to raise their arms parallel to … Continue reading →

Editor's Choice Academic Journal Main Category: Schizophrenia Also Included In: Genetics;Psychology / Psychiatry Article Date: 19 May 2012 - 9:00 PDT Current ratings for: 'Genetic Test May Predict Risk Of Schizophrenia' 4.67 (3 votes) 5 (1 votes) Combined, these genes can generate a score, and determine whether an individual is at lower or higher risk of developing schizophrenia. The study, which was conducted along with a group of national and international collaborators, is published online in the journal Molecular Psychiatry. In addition, the authors applied their top genes to data from other studies of schizophrenia and were able to successfully identify which patients had been diagnosed with the disease and which had not. When they examined the biological pathways in which the genes were active, they also proposed a model of schizophrenia, given that the disease's underlying causes are a mix of genetic variations that affect the development of the brain and neuronal connections together with environmental factors; in particular stress. Lead researcher, Alexander B. Niculescu III, M.D., Ph.D., associate professor of psychiatry and medical neuroscience at the IU School of Medicine, and director of the Laboratory of Neurophenomics at the IU Institute of Psychiatric Research, said: Niculescu, who is … Continue reading →

Indian clinic's stem cell therapy real? STORY HIGHLIGHTS For more of CNN correspondent Drew Griffin's investigation of India's experimental embryonic stem cell therapy, watch "CNN Presents: Selling a Miracle," at 8 and 11 p.m. ET Sunday on CNN. New Delhi (CNN) -- Cash Burnaman, a 6-year-old South Carolina boy, has traveled with his parents to India seeking treatment for a rare genetic condition that has left him developmentally disabled. You might think this was a hopeful mission until you learn that an overwhelming number of medical experts insist the treatment will have zero effect. Cash is mute. He walks with the aid of braces. To battle his incurable condition, which is so rare it doesn't have a name, Cash has had to take an artificial growth hormone for most of his life. His divorced parents, Josh Burnaman and Stephanie Krolick, are so driven by their hope and desperation to help Cash they've journeyed to the other side of the globe and paid tens of thousands of dollars to have Cash undergo experimental injections of human embryonic stem cells. The family is among a growing number of Americans seeking the treatment in India -- some at a clinic in the heart … Continue reading →

Indian clinic's stem cell therapy real? STORY HIGHLIGHTS For more of CNN correspondent Drew Griffin's investigation of India's experimental embryonic stem cell therapy, watch "CNN Presents: Selling a Miracle," at 8 and 11 p.m. ET Sunday on CNN. New Delhi (CNN) -- Cash Burnaman, a 6-year-old South Carolina boy, has traveled with his parents to India seeking treatment for a rare genetic condition that has left him developmentally disabled. You might think this was a hopeful mission until you learn that an overwhelming number of medical experts insist the treatment will have zero effect. Cash is mute. He walks with the aid of braces. To battle his incurable condition, which is so rare it doesn't have a name, Cash has had to take an artificial growth hormone for most of his life. His divorced parents, Josh Burnaman and Stephanie Krolick, are so driven by their hope and desperation to help Cash they've journeyed to the other side of the globe and paid tens of thousands of dollars to have Cash undergo experimental injections of human embryonic stem cells. The family is among a growing number of Americans seeking the treatment in India -- some at a clinic in the heart … Continue reading →

Editor's Choice Main Category: Pediatrics / Children's Health Also Included In: Stem Cell Research Article Date: 20 May 2012 - 11:00 PDT Current ratings for: 'World's First Stem Cell Drug From Osiris : Approved!' 5 (1 votes) The decision is a historic one, as it's both the first stem cell drug going into formal use, as well as the first treatment for GvHD. The disease is a devastating breakdown occurring after a bone marrow transplant and kills around 80% of children affected, often within a matter of weeks. Andrew Daly, M.D., Clinical Associate Professor, Department of Medicine and Oncology at the University of Calgary, Canada and Principal Investigator in the phase 3 clinical program for Prochymal confirmed : The approval process for Prochymal was implemented under Health Canada's Notice of Compliance with conditions (NOC/c) pathway. The basis of the procedure allows a new drug to come onto the market where there are unmet medical needs. The approval is granted with the provision that the drug has demonstrated risk / reward benefits in previous clinical trials and that the manufacturer agrees to undertake additional confirmatory clinical testing. C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris confirmed his' companies … Continue reading →

Public release date: 20-May-2012 [ | E-mail | Share ] Contact: Charlotte Hsu chsu22@buffalo.edu 716-645-4655 University at Buffalo BUFFALO, N.Y. -- A pioneering study to gauge the toxicity of quantum dots in primates has found the tiny crystals to be safe over a one-year period, a hopeful outcome for doctors and scientists seeking new ways to battle diseases like cancer through nanomedicine. The research, which will appear on May 20 in Nature Nanotechnology online, is likely the first to test the safety of quantum dots in primates. The study and information in this press release are embargoed until Sunday, May 20, 2012 at 1 p.m. U.S. Eastern Standard Time. In the study, scientists found that four rhesus monkeys injected with cadmium-selenide quantum dots remained in normal health over 90 days. Blood and biochemical markers stayed in typical ranges, and major organs developed no abnormalities. The animals didn't lose weight. Two monkeys observed for an additional year also showed no signs of illness. Quantum dots are tiny luminescent crystals that glow brightly in different colors. Medical researchers are eyeing the crystals for use in image-guided surgery, light-activated therapies and sensitive diagnostic tests. Cadmium selenide quantum dots are among the most studied, … Continue reading →